• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times?

作者信息

Ferrara Francesco, Porta Raffaele La, Santilli Priscilla, D'Aiuto Vilma, Vitiello Antonio

机构信息

Department of Pharmaceutical, Usl Umbria 1, Perugia, Italy.

Department of Clinical Pathology, Asur Marche, Macerata, Italy.

出版信息

Indian J Pharmacol. 2020 Sep-Oct;52(5):441-442. doi: 10.4103/ijp.IJP_417_20.

DOI:10.4103/ijp.IJP_417_20
PMID:33283779
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8025773/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a720/8025773/d42c2ead4059/IJPharm-52-441-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a720/8025773/d42c2ead4059/IJPharm-52-441-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a720/8025773/d42c2ead4059/IJPharm-52-441-g001.jpg

相似文献

1
Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times?多发性硬化症疗法在感染严重急性呼吸综合征冠状病毒2的情况下是否安全？
Indian J Pharmacol. 2020 Sep-Oct;52(5):441-442. doi: 10.4103/ijp.IJP_417_20.
2
Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.COVID-19 疫情对多发性硬化症患者免疫治疗的影响——从 SARS 和 MERS 中吸取的教训。
Front Immunol. 2020 May 12;11:1059. doi: 10.3389/fimmu.2020.01059. eCollection 2020.
3
The pressing questions in multiple sclerosis Care in the era of COVID-19.新冠疫情时代多发性硬化症护理的当务之急。
J Neurol Sci. 2020 Sep 15;416:117005. doi: 10.1016/j.jns.2020.117005. Epub 2020 Jun 23.
4
The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic.控制多发性硬化症的免疫治疗策略：COVID-19 大流行期间的考虑因素。
Biomolecules. 2021 Sep 17;11(9):1372. doi: 10.3390/biom11091372.
5
Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis.新型冠状病毒肺炎导致视神经脊髓炎谱系障碍和多发性硬化症患者及医生态度的变化。
Mult Scler Relat Disord. 2020 Jul;42:102259. doi: 10.1016/j.msard.2020.102259. Epub 2020 Jun 3.
6
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.新冠病毒肺炎在一名多发性硬化症患者中发作，该患者由于最近接受克拉屈滨治疗而出现严重的淋巴细胞减少症。
Mult Scler. 2020 Sep;26(10):1264-1266. doi: 10.1177/1352458520943783. Epub 2020 Aug 7.
7
Multiple sclerosis and COVID-19: A great opportunity for databases promoting research and collaboration.多发性硬化症与2019冠状病毒病：数据库推动研究与合作的绝佳机遇。
J Neuroimmunol. 2020 Aug 15;345:577283. doi: 10.1016/j.jneuroim.2020.577283. Epub 2020 May 31.
8
Risk stratification and mitigation multiple sclerosis.风险分层与缓解多发性硬化症
Mult Scler Relat Disord. 2014 Sep;3(5):639-49. doi: 10.1016/j.msard.2014.05.003.
9
Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach.2019冠状病毒病大流行期间中枢神经系统脱髓鞘疾病的管理：一种实用方法。
Arq Neuropsiquiatr. 2020 Jul;78(7):430-439. doi: 10.1590/0004-282X20200056. Epub 2020 Jul 1.
10
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.用芬戈莫德和特立氟胺治疗的多发性硬化症患者中新冠病毒血清转化及病情进展缓慢情况
J Neurol Sci. 2020 Sep 15;416:117011. doi: 10.1016/j.jns.2020.117011. Epub 2020 Jul 4.

引用本文的文献

1
Long COVID could become a widespread post-pandemic disease? A debate on the organs most affected.长新冠可能成为一种广泛流行的后疫情疾病？关于受影响最严重的器官的争论。
Naunyn Schmiedebergs Arch Pharmacol. 2023 Jul;396(7):1583-1589. doi: 10.1007/s00210-023-02417-5. Epub 2023 Feb 11.
2
Pharmacological Agents with Antiviral Activity against Monkeypox Infection.具有抗猴痘感染病毒活性的药物制剂。
Int J Mol Sci. 2022 Dec 14;23(24):15941. doi: 10.3390/ijms232415941.
3
Pregnancy and COVID-19, focus on vaccine and pharmacological treatment.

本文引用的文献

1
Sacubitril, valsartan and SARS-CoV-2.沙库巴曲缬沙坦与严重急性呼吸综合征冠状病毒2
BMJ Evid Based Med. 2020 Jul 27. doi: 10.1136/bmjebm-2020-111497.
2
Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?肾素-血管紧张素系统与严重急性呼吸综合征冠状病毒 2 感染的相关性：我们了解多少？
Eur J Pharmacol. 2020 Sep 15;883:173373. doi: 10.1016/j.ejphar.2020.173373. Epub 2020 Jul 15.
3
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
妊娠与 COVID-19，关注疫苗和药物治疗。
J Reprod Immunol. 2022 Jun;151:103630. doi: 10.1016/j.jri.2022.103630. Epub 2022 Apr 21.
4
Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients.COVID-19患者肺纤维化状态的病理生理学及治疗前景
Curr Res Pharmacol Drug Discov. 2021;2:100056. doi: 10.1016/j.crphar.2021.100056. Epub 2021 Sep 16.
5
Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection.巴瑞替尼/瑞德西韦治疗成人 COVID-19 感染的关联观点。
Mol Biol Rep. 2022 Jan;49(1):827-831. doi: 10.1007/s11033-021-06888-8. Epub 2021 Nov 27.
6
The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced.新冠病毒感染患者肝损伤的风险以及降低或预防其所导致损伤的药物治疗。
Egypt Liver J. 2021;11(1):11. doi: 10.1186/s43066-021-00082-y. Epub 2021 Jan 27.
7
Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection.巴瑞替尼/瑞德西韦/重组人血管紧张素转化酶 2 三联药物疗法治疗 COVID-19 感染的关联和药理学协同作用。
Naunyn Schmiedebergs Arch Pharmacol. 2022 Jan;395(1):99-104. doi: 10.1007/s00210-021-02169-0. Epub 2021 Oct 20.
8
Plausible Positive Effects of Statins in COVID-19 Patient.他汀类药物对 COVID-19 患者可能产生积极影响。
Cardiovasc Toxicol. 2021 Oct;21(10):781-789. doi: 10.1007/s12012-021-09674-x. Epub 2021 Jul 13.
9
Logistics management provides greater efficiency, governance and compliance.物流管理提供更高的效率、治理和合规性。
Int J Clin Pharm. 2021 Oct;43(5):1431-1435. doi: 10.1007/s11096-021-01283-6. Epub 2021 Jun 13.
10
Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients.调节新冠病毒肺炎患者肾素-血管紧张素和利钠肽系统的药物制剂
Wien Klin Wochenschr. 2021 Sep;133(17-18):983-988. doi: 10.1007/s00508-021-01855-6. Epub 2021 Apr 20.
吡非尼酮在抗击由 SARS-CoV-2 引起的炎症和纤维化状态中的附加价值：抗炎和抗纤维化治疗能否解决感染的肺部并发症？
Eur J Clin Pharmacol. 2020 Nov;76(11):1615-1618. doi: 10.1007/s00228-020-02947-4. Epub 2020 Jun 27.
4
Infection-related health care utilization among people with and without multiple sclerosis.多发性硬化症患者与非多发性硬化症患者的感染相关医疗保健利用情况。
Mult Scler. 2017 Oct;23(11):1506-1516. doi: 10.1177/1352458516681198. Epub 2016 Dec 21.